GAM
IOVA icon

Griffin Asset Management’s Iovance Biotherapeutics IOVA Stock Holding History

Griffin Asset Management’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-940
Closed -$23K – 345
2019
Q2 		$23K Buy
+940
New +$14.2K ﹤0.01% 416

Other funds holding IOVA

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Griffin Asset Management's IOVA Position: Q3 2019 in Review

Griffin Asset Management sold out of Iovance Biotherapeutics (IOVA) in Q3 2019, closing a stake of 940 shares — an estimated $23K sold.

Griffin Asset Management first reported a position in IOVA in Q2 2019 and held it in 1 quarter. The position peaked at $23K in Q2 2019. 173 funds tracked by Wall St. Rank hold IOVA as of Q3 2019.

  • Griffin Asset Management reported no remaining Iovance Biotherapeutics position as of Q3 2019 after selling out during the quarter.
  • Griffin Asset Management sold 940 Iovance Biotherapeutics shares in Q3 2019, an estimated $23K.
  • Griffin Asset Management first reported a position in Iovance Biotherapeutics in Q2 2019 and held it in 1 quarter.
  • Griffin Asset Management's Iovance Biotherapeutics position peaked at $23K in Q2 2019.
  • 173 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q3 2019.

Based on Griffin Asset Management's 13F filing for Q3 2019, filed 5 Nov 2019.